FGL2 and neoplasm: In the IMvigor210 cohort, lower FGL2 expression was observed in the desert phenotype (patients with this phenotype were less likely to benefit from immunotherapy), IC0 (immune cells with the lowest PD-L1 values), and TC0 (tumor cells with the lowest PD-L1 values) groups (Figure 8H-J).